US › Healthcare

Pulmonx Corp (LUNG)

US · Healthcare · Medical Devices

$2.06-2.83%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$22.8M
Revenue YoY
-4.6%
Net profit
$-10.1M
Profit YoY
+33.6%
EPS
$-0.24
EPS estimate
$-0.28
Net margin
-44.3%

EPS came in at -0.24 against a street estimate of -0.28 — a beat of 14.3%.

Key statistics

Market cap
$68.8M
Forward P/E
28.3
P/B
1.76
Book value
$1.08
EPS (TTM)
$-1.15
52-week high
$2.89
52-week low
$1.13
50-day MA
$1.42
200-day MA
$1.61
Beta
0.31

Analyst view

Analysts rate Pulmonx Corp a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $3.40.

Shareholding

Insiders
4.88%
Institutions
78.63%

Largest institutional holders

FundStake
PRIMECAP Management Company11.19%
Morgan Stanley - Brokerage Accounts9.46%
Soleus Capital Management, L.P.6.60%
BlackRock Inc6.30%
ExodusPoint Capital Management, LP4.60%
Vanguard Capital Management, LLC3.87%
Bank of America Corp2.76%
Deutsche Bank AG2.76%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pulmonx Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.